Needham and Cantor Fitzgerald initiate 'Buy' ratings while unconfirmed partnership rumors with Tesla fuel significant buying pressure.
Ascendiant Capital Markets raises its price target to $22, calling the e-commerce company 'very undervalued' after a stellar Q2 performance.
FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The strategic partnership for 6 gigawatts of GPU deployment challenges Nvidia's dominance and signals a new era in AI infrastructure.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Shares surged over 100% in after-hours trading following a $35.6 million investment to advance a strategic mining project in Alaska.
The dilutive share offering at $1.25 per share comes just a week after the energy storage company's stock surged over 100%.
Taiwan Semiconductor hits a 52-week high while AMD and OpenAI announce a landmark chip deal, signaling sustained bullish momentum for chipmakers.